New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...

Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS) NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility...

New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care Study Presented At the Society for Critical Care Medicine (SCCM) 50th Congress NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) the global leader in blood volume...